Journal of cancer research and therapeutics最新文献

{"title":"Primary testicular lymphoma: A case report.","authors":"Sharmistha Roy, Tej Prakash Soni, Upendra Sharma, Anjali Sharma","doi":"10.4103/jcrt.jcrt_1482_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1482_22","url":null,"abstract":"<p><strong>Abstract: </strong>Primary testicular lymphoma is a rare and aggressive form of extranodal non-Hodgkin lymphoma. It has a predilection for relapse at sanctuary sites such as the contralateral testis and central nervous system. Herein, we present a case of primary testicular lymphoma in a 62-year-old man.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"186-188"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The current status of cervical cancer awareness and HPV Vaccination among rural women of India: An impediment to the WHO cervical cancer elimination initiative.","authors":"Lajya Devi Goyal, Priyanka Garg, Ankita Kankaria, Navdeep Kaur","doi":"10.4103/jcrt.jcrt_244_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_244_24","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer screening and the HPV (human papillomavirus) vaccination rates are low in India, with widespread socio-economic disparities and inadequate awareness about the symptoms, risk factors, and available preventive methods. The problem is more concerning in rural areas. So, the present study aimed to precisely assess the awareness of the women (18-65 years) residing in rural areas regarding cervical cancer and HPV vaccines.</p><p><strong>Methods: </strong>A community-based cross-sectional study was conducted in three districts of Punjab in 2021 and included 600 participants through a multistage random sampling technique. Data were collected using a pretested semistructured questionnaire. Awareness was assessed using a comprehensive scoring system. Descriptive statistics and Bivariate analyses were used to present the results.</p><p><strong>Results: </strong>Ninety percent of participants had heard of cervical cancer, but only 1.8% had comprehensive knowledge. About 55.5% of the participants were not ready for screening, and most (34.2%) were confident they would not have cancer in their lifetime. Only 5.3% had heard of the HPV vaccine, and very few (0.5%) participants were vaccinated. The most commonly cited reasons were lack of knowledge (90.1%) and the high cost of vaccines (5.9%).</p><p><strong>Conclusions: </strong>The present study depicts diffuse knowledge about cervical cancer and low uptake of HPV vaccination in rural areas, not affected by sociodemographic characteristics. This calls for large-scale health advocacy programs to promote regular screening to generate demand and improve acceptance of the soon-to-be-launched indigenous HPV vaccine in the Universal Immunization program and achieve the WHO global target of eliminating cervical cancer by 2030.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"57-63"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144046754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Occurrence patterns of reported gastrointestinal cancers and its correlation with psychological issues due to cancer diagnosis and its treatments - An epidemiological study.","authors":"Renu Pattanshetty, Mounica S Rao","doi":"10.4103/jcrt.JCRT_1080_20","DOIUrl":"https://doi.org/10.4103/jcrt.JCRT_1080_20","url":null,"abstract":"<p><strong>Context: </strong>Cancer is regarded as the leading cause of mortality and disabilities worldwide. Gastrointestinal (GI) cancer is the fifth highest cancer accounting for 5.7% of all cancers worldwide. Cancer diagnosis and its treatment have an impact on the patients' physical and psychological well-being.</p><p><strong>Aim: </strong>To know the occurrence patterns of reported GI cancers and its correlation with psychological issues such as depression, anxiety, and cognition due to cancer diagnosis and its treatments.</p><p><strong>Methods: </strong>This epidemiological study was conducted at KLE Hospital and Medical Research Centre in Belagavi city, Karnataka, India for a period of 3 months. Data of 61 patients were collected using Zung depression scale, general anxiety disorder-7 (GAD-7), functional assessment of cancer therapy-cognitive function (FACT-Cog), and FCSI for depression, anxiety, cognition, and quality of life (QOL), respectively.</p><p><strong>Results: </strong>The mutual risk factor of 61 patients was tobacco consumption, cigarette smoking, and alcohol consumption (P = 0.001) with majority of the cases being carcinoma of buccal cavity (n = 14). A poor correlation among the type of GI cancers, its stage, and treatment to depression, anxiety, and cognition were noted.</p><p><strong>Conclusion: </strong>This study concludes that there is an association between the risk factor and the occurrence pattern, and an overall poor correlation of the cancer diagnosis and its treatment with the psychological issues such as depression, anxiety, and cognition.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"10-15"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Craniospinal irradiation for medulloblastoma tumors: Retrospective analysis of dosimetric comparison-An institutional study.","authors":"Rama Devi, Balbir Singh, Deepak Basandrai","doi":"10.4103/jcrt.jcrt_2305_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2305_23","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;The comparative study of dosimetric parameters for craniospinal irradiation (CSI) in medulloblastoma cancer patients has been conducted using three different radiation treatment modalities, such as helical intensity-modulated radiation therapy (RT) (HIMRT), helical three-dimensional (3D) conformal RT (H3DCRT), and volumetric modulated arc therapy (VMAT). Evaluation based on dosimetric parameters has been performed to check the better clinical outcomes of recent treatment techniques over one another.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Materials and methods: &lt;/strong&gt;In this retrospective study, twenty patients have been taken who were suffering from average-risk medulloblastoma. For these patients, phase 1 and phase 2 treatment plans were generated with HIMRT, H3DCRT, and VMAT using Accuray Precision version 2.0.1.1 and Monaco version 5.51.10 treatment planning software (TPS). For dose calculation, the convolution superposition algorithm is used for HIMRT and H3DCRT and the Monte Carlo algorithm is used for VMAT.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Result: &lt;/strong&gt;Homogeneity index (HI), conformity index (CI), heterogeneity index (HT), total treatment time (TT), and doses to organs at risk (OARs) have been calculated. Statistical analysis has been performed with a paired-samples test in Statistical Package for the Social Sciences (SPSS) software version 22. For target volume PTV_Brain, Conformity index in different treatment techniques are mentioned (HIMRT = 1.02 ± 0.016, H3DCRT = 1.04 ± 0.015, VMAT = 1.11 ± 0.090), homogeneity indexes is (HIMRT = 0.73 ± 0.088, H3DCRT = 0.39 ± 0.208, VMAT = 0.43 ± 0.102), and Heterogeneity index is (HIMRT = 1.51 ± 0.013, H3DCRT = 1.50 ± 0.017, VMAT = 1.09 ± 0.018). For target volume PTV_Spine Conformity index in different treatment techniques are mentioned (HIMRT = 1.00 ± 0.004, H3DCRT = 1.01 ± 0.013, VMAT = 1.07 ± 0.039), homogeneity indexes is (HIMRT=0.07 ± 0.043, H3DCRT =0.06 ± 0.070, VMAT = 0.23 ± 0.183), and Heterogeneity index is (HIMRT = 1.10 ± 0.12, H3DCRT = 1.11 ± 0.121, VMAT = 1.06 ± 0.007). For target volume Boost_GTV Conformity index in different treatment techniques are mentioned (HIMRT = 1.035 ± 0.016, H3DCRT = 1.04 ± 0.016, VMAT = 1.08 ± 0.05), homogeneity indexes is (HIMRT = 0.80 ± 0.090, H3DCRT = 0.44 ± 0.223, VMAT = 0.56 ± 0.105), and Heterogeneity index is (HIMRT = 1.27 ± 0.006, H3DCRT = 1.26 ± 0.009, VMAT = 1.07 ± 0.009). Total Treatment time (minutes) for phase 1 in different techniques (HIMRT = 17.77 ± 3.974, H3DCRT = 14.83 ± 3.750, VMAT = 9.72 ± 0.713) and for phase 2 treatment time (HIMRT = 1.99 ± 0.306, H3DCRT = 1.68 ± 0.326, VMAT = 3.39 ± 0.918). All techniques, such as HIMRT, H3DCRT, and VMAT, give a uniform and conformal target coverage, but HIMRT shows the best conformal and homogeneous dose distribution and better OAR sparing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In this study, CSI patients treated with HIMRT showed better results in terms of conformity, homogeneity, and doses to organs at risk","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"40-48"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144058200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation of immune profiling and exceptional response to immune checkpoint inhibitor in a patient with head and neck cancer.","authors":"Kriti Jain, Deepak K Rathore, Surajit Ganguly, Akshay Binayke, Nirmal K Ganguly, Amit Awasthi, Shyam Aggarwal","doi":"10.4103/jcrt.jcrt_2339_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2339_22","url":null,"abstract":"<p><strong>Abstract: </strong>Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer therapy and it is a huge step forward in the treatment of various cancers including head and neck cancer. Nivolumab, an anti-PD-1 monoclonal antibody, reportedly has improved overall survival in head and neck cancer, yet only a subset of patient population benefit from it. Tissue-based markers such as PD-L1expression positive, tumor mutation burden-high, and microsatellite instability-high are widely believed to be a biomarker for ICIs such as nivolumab in solid tumors. However, due to the low prevalence of microsatellite instability-high and tumor mutation burden-high in most cancers and PD-L1 negative tumor responding well to ICIs, it tends to be insufficient to identify whether patients should receive ICIs as per this biomarker alone. Mechanism of response to checkpoint inhibitor therapy is unclear and hence studying the role of immune cells and pathways involved is important. The role played by peripheral blood parameters remains ambiguous. Here in, we present a case of an 85-year-old patient with advanced carcinoma buccal mucosa who was treated with Nivolumab after failure of chemotherapy and radiotherapy. Considering the limitations of tissue-based biomarkers to predict response to ICIs, we aimed to identify which blood-based biomarkers correlated with the response to treatment and monitored the immune parameters and serum cytokine levels during the course of Nivolumab. Here in, we also describe the clinical presentation of patient during the course of this therapy. Blood samples were collected pretherapy and post-therapy to monitor the response. Both clinical and immunological differences in the composition of Ki67+ PD-1+ CD8 T cells, Granzyme B+ CD8 T cells, NK and NKT cells, and serum cytokine levels of TNF alpha were observed to be elevated post-ICIs during monitoring of the patient receiving checkpoint inhibitor therapy. Monitoring these circulating peripheral blood markers in wider population of patients receiving ICI therapy, during its course, may provide a perspective in the development of new biomarkers for predicting response and may serve as a basis for personalized treatment. This case report describes valuable insights into evolution of immune markers predicting and monitoring response to Nivolumab in a patient with cancer.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"205-209"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The need for quality-of-life data among cancer patients: Addressing disparities and leveraging technology.","authors":"Rahul Kashyap, Navesh Sharma, Daya Nand Sharma","doi":"10.4103/jcrt.jcrt_2267_24","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2267_24","url":null,"abstract":"","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Robustness analysis to mitigate setup uncertainties in head-neck rapid arc treatment: A different approach to image-guided radiotherapy decision-making.","authors":"Soumya Roy, Anusheel Munshi, Biplab Sarkar, Anirudh Pradhan, Vikash Kumar Pandey, J Maria Asha","doi":"10.4103/jcrt.jcrt_1337_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1337_23","url":null,"abstract":"<p><strong>Aim: </strong>The occurrence of setup errors in external beam radiation is an inevitable aspect. As a result of technological progress in image verification, it became feasible to decrease its occurrence; however, complete eradication remained unattainable. Various methodologies have been implemented in clinical settings to measure and evaluate the extent of setup mistakes. Further analysis is required to gain a deeper understanding of the effects of setup mistakes on dose-volume histograms (DVHs), which will inform decision-making in the context of setup-related issues. This study aimed to quantify the extent of deviation observed in the DVH when a specific shift in a particular direction occurs within a pre-defined limit.</p><p><strong>Material and methods: </strong>Four head and neck patients were planned with Rapidarc modality using Eclipse™. The cone beam computed tomography image was acquired using Portal vision. Everyday, the treatment setup error was obtained from the offline review system. Plan data were imported into Computational Environment for Radiological Research software, and the perturbation of the DVH due to setup error was generated retrospectively. A total of 92 patient images and associated setup error information were analyzed in this study.</p><p><strong>Results: </strong>Variations of dose to planning target volume (PTV) and organ at risk (OAR) using different parameters were analyzed to assess the uncertainty associated with day-to-day setup error, and intentional perturbation in DVH due to simulated error in all three Cartesian directions was analyzed. A low and moderate statistical correlation existed between the two patients' deviation in DVH due to the same amount of shift in the case of OAR. However, a positive correlation existed between the patients for PTV-related parameters.</p><p><strong>Conclusion: </strong>Knowing the impact of shift data in DVH was helpful information that could be utilized further for different study data sets to see the contribution of shift data to dose uncertainty. For the PTV class, a solution for intentional shifts may be possible. For OAR dose simulation, individual patient-based simulation is required. This robustness analysis will help the user understand the setup error's implication in the DVH.</p><p><strong>Advance in knowledge: </strong>The present-day image-guided radiation therapy system was based on landmark matching based on different objectives. The standard linear accelerator-based setup or cobalt-based external beam radiotherapy (EBRT) setup had no information regarding the effect of the shift in DVH. This robustness analysis under the MATLAB platform was an effective tool for evaluating the setup error's impact on the DVH.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"22-33"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144001128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isolated IgG4-related disease of terminal ileum: Report of a rare case and review of literature.","authors":"Subham Bhowmik, Hemanga K Bhattacharjee, Joyner Abraham, Raju Sharma, Prasenjit Das","doi":"10.4103/jcrt.jcrt_1693_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1693_22","url":null,"abstract":"<p><strong>Abstract: </strong>Among the class of immune-mediated diseases, immunoglobulin G4-related diseases (IgG4-RDs) are of particular interest due to their occurrence in a vast number of organ systems with varied presentations. Isolated bowel involvement in IgG4-RD is, however, very rare. A 54-year-old woman presented with acute-onset colicky abdominal pain located in the right lower quadrant for the past 6 months with abdominal distention. Abdominal contrast-enhanced computed tomography (CECT) depicted short-segment symmetrical and circumferential thickening of distal ileal loops and the ileocecal junction with accompanying mesenteric lymphadenopathy, raising the possibilities of ileocecal tuberculosis or Crohn's disease, or malignancy. A right hemicolectomy was performed, and the histological examination revealed it to be an isolated ileal IgG4-RD. After a one-year follow-up, no radiological or clinical recurrence or related symptom was noted. This is the second reported case of isolated ileal IgG4-RD to the best of our knowledge, and IgG4-RD should be kept in mind even when the patient presents with segmental bowel thickening along with common possibilities such as tuberculosis or Crohn's disease in this anatomical region.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"200-204"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144045170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of liver metastases (oligometastatic) by high-dose-rate interstitial brachytherapy: A case series.","authors":"Ashok Kumar, Manoj Gopinath, Manoj K Semwal","doi":"10.4103/jcrt.jcrt_356_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_356_23","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the feasibility, efficacy, and safety of interstitial brachytherapy in cases of oligo-metastatic liver disease.</p><p><strong>Materials and method: </strong>Four cases of liver metastases were managed over a period of 1 year in our center with close follow-up. All patients had progressive disease with histopathologially proven liver metastases and were ineligible for surgery. The procedure involved placement of brachytherapy catheters under computed tomography (CT) guidance post placement of a single 6F angiography sheath. The median size of metastasis was 2.9 cm (range 2.2-3.4 cms) in diameter, and a single fraction of radiation dose (10 to 13 Gy) was delivered. The angiography sheath and brachytherapy catheters were removed under fluoroscopic guidance post completion of the procedure with the help of an interventional radiologist. The fluoro guidance for removal of catheters was to observe any bleed. Response to treatment in terms of control of the metastases along with complications, safety, and efficacy of the procedure was observed.</p><p><strong>Results: </strong>All patients underwent re-evaluation with WB-PET-CT after 1 and 6 months. In three cases, complete response with no metabolic activity was noted on WB-PET-CT scan, and in one case, there was a partial response with a decrease in the size and metabolic activity of the metastasis. No fatal complications were noted; however, acute complications like grade 1 nausea, grade 1 vomiting, pain, and local hemorrhage were noted within 1 week of the procedure.</p><p><strong>Conclusion: </strong>Liver interstitial brachytherapy is a feasible option in patients with maybe oligo metastatic solid tumors requiring a multi-disciplinary team effort. It is also an option for patients who are unfit for surgical excision. This is the first reported case series in India using high-dose-rate (HDR) brachytherapy techniques with an angiography sheath and flexible brachytherapy catheters.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 1","pages":"49-56"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab emtansine induced hyponatremia in breast cancer - A case report.","authors":"Firoz Pareeth, Geethu Babu, Beela Sarah Mathew","doi":"10.4103/jcrt.jcrt_1602_23","DOIUrl":"10.4103/jcrt.jcrt_1602_23","url":null,"abstract":"<p><strong>Abstract: </strong>Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), approved for use as an adjuvant treatment for patients with residual disease after neoadjuvant chemotherapy and antihuman epidermal growth factor receptor 2 (HER-2) therapy and in metastatic HER-2-positive breast cancer. Previous studies have shown that T-DM1 has a favorable safety profile, with few high-grade toxicities reported so far. We describe a patient who developed profound hyponatremia-which has not been reported previously-following treatment with adjuvant T-DM1 for HER-2+ breast cancer.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"240-242"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}